Rocket Pharma ( (RCKT) ) has released its Q2 earnings. Here is a breakdown of the information Rocket Pharma presented to its investors.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Rocket Pharmaceuticals, Inc. is a biotechnology company specializing in genetic therapies for rare and complex disorders, with a focus on both cardiovascular and hematology portfolios. In its latest earnings report for the quarter ended June 30, 2025, Rocket Pharma highlighted its strategic focus on gene therapy platforms, particularly in cardiovascular diseases, despite ongoing challenges. The company reported a net loss of $68.9 million for the quarter, with total operating expenses reaching $71.1 million, reflecting its continued investment in research and development. Rocket Pharma’s cash and investments totaled $271.5 million, which the company expects to sustain operations into the second quarter of 2027. Looking forward, Rocket Pharmaceuticals remains committed to advancing its gene therapy programs while navigating financial and operational challenges to achieve long-term growth and innovation.